Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO/Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb tells Advanced Medical Optics July 24 that AMO's June 29 offer to buy B&L for $75 per share in cash and stock - about $4.3 billion - "would not be likely to result in a superior proposal" versus Warburg Pincus' $65-per-share cash offer announced in May (1"The Gray Sheet" July 9, 2007, In Brief). In response, AMO reaffirmed its $75 per share offer, which it believes "fully and fairly values" B&L, and offered to pay an increased fee if AMO shareholders reject the deal. AMO also provided additional assurances that its shareholders would support the purchase..

You may also be interested in...



Bausch & Lomb bidding escalates

Advanced Medical Optics offers to buy rival ophthalmic device firm Bausch & Lomb for $75 per share in cash and stock - or $4.3 billion - to trump private equity firm Warburg Pincus' $65-per-share cash offer announced in May. B&L said July 5 it will consider AMO's proposal, which is contingent in part on additional due diligence. AMO indicated it was considering a bid shortly after the original Warburg agreement (1"The Gray Sheet" May 28, 2007, p. 21). However, AMO management's focus on a subsequent recall of its Complete MoisturePlus contact lens solution had threatened to derail the effort (2"The Gray Sheet" June 4, 2007, p. 10)...

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.

UsernamePublicRestriction

Register

MT025060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel